SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Sinclair Michael (Last) (First) (Middle) 445 PARK AVENUE, 9TH FLOOR (Street) NEW YORK NY 10022 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Lightlake Therapeutics Inc. [ LLTP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) Executive Chairman
	3. Date of Earliest Transaction (Month/Day/Year) 12/10/2014
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.001 per share(1)(2)	01/10/2012		A		5,000	A	(3)	37,720	I	Proton Therapy USA
Common stock, par value $0.001 per share	10/21/2013		A		20,000	A	(3)	57,720	D
Common stock, par value $0.001 per share	01/15/2015		S		1,700	A	$3.5	75,585	D
Common stock, par value $0.001 per share	01/16/2015		A		1,700	A	$3.69	77,285	D
Common stock, par value $0.001 per share	01/20/2015		A		1,600	A	$3.69	78,885	D
Common stock, par value $0.001 per share	01/21/2015		A		1,500	A	$3.94	80,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options(4)	$8	05/01/2013(5)		A		130,000		05/01/2013(5)	04/30/2023(5)	Common Stock, par value $0.001 per share	130,000	(6)	475,000	D
Options	$10	05/01/2013(7)		A		105,000		05/01/2013(7)	04/30/2023(7)	Common Stock, par value $0.001 per share	105,000	(6)	580,000	D
Options	$15	08/01/2013		A		50,000		08/01/2013	07/31/2023	Common Stock, par value $0.001 per share	50,000	(6)	630,000	D
Options	$20	08/01/2013		A		50,000		08/01/2013	07/31/2023	Common Stock, par value $0.001 per share	50,000	(6)	680,000	D
Options	$6	12/31/2013		A		75,000		12/31/2013	12/30/2023	Common Stock, par value $0.001 per share	75,000	(6)	755,000	D
Options	$5	06/15/2014		A		150,000		06/15/2014(8)	06/14/2024	Common Stock, par value $0.001 per share	150,000	(6)	905,000	D
Options	$8	06/15/2014		A		100,000		06/15/2014(8)	06/14/2024	Common Stock, par value $0.001 per share	100,000	(6)	1,005,000	D
Options	$7.25	10/27/2015		A		250,000		10/27/2015(9)	10/26/2025	Common Stock, par value $0.001 per share	250,000	(6)	1,255,000	D

Explanation of Responses:

1. This Form 4 is a late filing reporting the changes in beneficial ownership of the Reporting Person as of November 6, 2015. This Form 4 was required to be filed within two business days of 12/10/2014, the effective date of the Issuer's Form 8-A registration statement which registered the common stock of the Issuer for the first time under Section 12 of the Exchange Act. The Reporting Person voluntarily filed a Form 3 and a Form 4 on May 31, 2012 and voluntarily filed another Form 4 on January 25, 2013. In December 2014, the Issuer effected a one-for-one hundred reverse stock split of its common stock (the "1:100 Reverse Stock Split"). Unless otherwise noted, all share amounts and exercise prices listed in this Form 3 been retroactively adjusted for the 1:100 Reverse Stock Split as if such stock splits occurred prior to the issuance of such shares, warrants, or options.

2. Footnote 1 continued - As of the January 25, 2013 Form 4, the Reporting Person owned 50,820 shares of the Issuer's common stock: 23,820 shares; 15,000 owned indirectly through the Reporting Person's wife; 12,000 owned indirectly through joint pension funds. Since January 25, 2013, the Reporting Person's wife transferred her 15,000 shares to the Reporting Person for no consideration and there are 1,935 shares that the Reporting Person no longer owns whose disposition is unclear. Thus, for purposes of this Form 4, the Reporting Person owned 48,885 shares prior to the first transaction reported on this Form 4.

3. Unknown.

4. As of the January 25, 2013 Form 4, the Reporting Person owned 345,000 derivative securities: 60,000 shares of common stock issuable upon exercise of stock options and 285,000 shares of common stock issuable upon the exercise of warrants.

5. 50,000 vested on 5/1/2013, 50,000 vested on 11/1/2013, and 30,000 vested on 12/31/2013. All expire 10 years after their respective vesting dates.

6. Cashless Options.

7. 25,000 vested on 5/1/2013, 25,000 vested on 8/1/2013; 25,000 vested on 11/1/13, and 30,000 vested on 12/31/13. All expire 10 years after their respective vesting dates.

8. These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of the next trial with respect to the opioid overdose reversal treatment; (B) the entrance into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment; or (C) the filing of a New Drug Application with the U.S. Food and Drug Administration with respect to the opioid overdose reversal treatment; and (ii) the Expiration Date.

9. These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date.

	/s/ Michael Sinclair	11/06/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.